New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

Icotrokinra helped 66% of patients with scalp psoriasis and 77% of those with genital psoriasis achieve significantly clear skin compared to 11% and 21% success rate in patients on placebo ...